sodium phenylbutyrate/tauroursodeoxycholic acid; sodium phenylbutyrate/taurursodiol (Relyvrio, AMX0035)
Jump to navigation
Jump to search
Indications
- investigational treatmment for amyotrophic lateral sclerosis (ALS)
* failed ALS drug, pulled from U.S. & Canadian market
Clinical significance
- median time to first hospitalization > 64 weeks (median time for placebo)
- median time to death or need for tracheostomy/permanent assisted ventilation 104 weeks vs 80 weeks for placebo[2]
More general terms
Components
- phenylbutyrate (Buphenyl, Olpruva)
- tauroursodeoxycholic acid; tauroursodeoxycholate; taurursodiol; taurolite
References
- ↑ Paganoni S Trial of Sodium Phenylbutyrate - Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med 2020; 383:919-930. Sept 3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32877582 https://www.nejm.org/doi/full/10.1056/NEJMoa1916945
George J Early Data for ALS Drug Show Survival Benefit - Mortality cut 44% over follow-up period MedPage Today October 16, 2020 https://www.medpagetoday.com/neurology/generalneurology/89172 - ↑ 2.0 2.1 Susman E Novel ALS Drug Continues to Show Survival Benefit. Median time to first hospitalization not yet reached with AMX0035 in CENTAUR trial. MedPage Today. April 19, 2021 https://www.medpagetoday.com/meetingcoverage/aan/92166
Paganoni S et al Long-term survival of participants in the CENTAUR trial of AMX0035 for ALS. American Academy of Neurology (AAN) 2021 - ↑ Bagha S Amylyx pulls ALS drug Relyvrio from market in US, Canada. Healio. April 4, 2024 https://www.healio.com/news/neurology/20240404/amylyx-pulls-als-drug-relyvrio-from-market-in-us-canada